Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer.
Kazuki NishimuraKyosuke NishioKensuke HirosunaKazumasa KomuraTakuo HayashiWataru FukuokayaAyako UraTaizo UchimotoKo NakamuraTatsuo FukushimaYusuke YanoNobushige TakahashiKeita NakamoriShoko KinoshitaTomohisa MatsunagaTakeshi TsutsumiTakuya TsujinoKohei TaniguchiTomohito TanakaHirofumi UeharaKiyoshi TakaharaTeruo InamotoYoshinobu HiroseTakahiro KimuraShin EgawaHaruhito AzumaPublished in: Journal for immunotherapy of cancer (2022)
The efficacy of pembrolizumab for patients previously treated with CRT was similar to those treated with TC. The enhanced tumor regression by combining programmed cell death protein 1/PD-L1 inhibitor and CRT might be expected only in the concurrent administration.